O08863
Gene name |
Birc3 |
Protein name |
Baculoviral IAP repeat-containing protein 3 |
Names |
EC 2.3.2.27 , Cellular inhibitor of apoptosis 2 , C-IAP2 , Inhibitor of apoptosis protein 1 , mIAP1 , RING-type E3 ubiquitin transferase BIRC3 |
Species |
Homo sapiens (Human) |
KEGG Pathway |
mmu:11796 |
EC number |
3.6.4.13: Acting on ATP; involved in cellular and subcellular movement |
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
553-598 (RING domain) |
Relief mechanism |
Ligand binding |
Assay |
|
Target domain |
553-598 (RING domain) |
Relief mechanism |
Ligand binding |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for O08863
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-O08863-F1 | Predicted | AlphaFoldDB |
No variants for O08863
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| No variants for O08863 | |||||
No associated diseases with O08863
Functions
| Description | ||
|---|---|---|
| EC Number | 3.6.4.13 | Acting on ATP; involved in cellular and subcellular movement |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
3 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| protein-containing complex | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. |
4 GO annotations of molecular function
| Name | Definition |
|---|---|
| cysteine-type endopeptidase inhibitor activity involved in apoptotic process | Binds to and stops, prevents or reduces the activity of a cysteine-type endopeptidase involved in the apoptotic process. |
| metal ion binding | Binding to a metal ion. |
| protein-containing complex binding | Binding to a macromolecular complex. |
| ubiquitin protein ligase activity | Catalysis of the transfer of ubiquitin to a substrate protein via the reaction X-ubiquitin + S -> X + S-ubiquitin, where X is either an E2 or E3 enzyme, the X-ubiquitin linkage is a thioester bond, and the S-ubiquitin linkage is an amide bond |
11 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| cellular response to tumor necrosis factor | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus. |
| necroptotic process | A programmed necrotic cell death process which begins when a cell receives a signal (e.g. a ligand binding to a death receptor or to a Toll-like receptor), and proceeds through a series of biochemical events (signaling pathways), characterized by activation of receptor-interacting serine/threonine-protein kinase 1 and/or 3 (RIPK1/3, also called RIP1/3) and by critical dependence on mixed lineage kinase domain-like (MLKL), and which typically lead to common morphological features of necrotic cell death. The process ends when the cell has died. The process is divided into a signaling phase, and an execution phase, which is triggered by the former. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| negative regulation of necroptotic process | Any process that decreases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. |
| negative regulation of phosphorylation | Any process that stops, prevents or decreases the rate of addition of phosphate groups to a molecule. |
| negative regulation of reactive oxygen species metabolic process | Any process that stops, prevents or reduces the frequency, rate or extent of reactive oxygen species metabolic process. |
| positive regulation of protein polyubiquitination | Any process that activates or increases the frequency, rate or extent of protein polyubiquitination. |
| positive regulation of protein ubiquitination | Any process that activates or increases the frequency, rate or extent of the addition of ubiquitin groups to a protein. |
| regulation of cell cycle | Any process that modulates the rate or extent of progression through the cell cycle. |
| regulation of non-canonical NF-kappaB signal transduction | Any process that modulates the frequency, rate or extent of NIK/NF-kappaB signaling. |
7 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q90660 | ITA | Inhibitor of apoptosis protein | Gallus gallus (Chicken) | SS |
| A1E2V0 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | Canis lupus familiaris (Dog) (Canis familiaris) | SS |
| Q96P09 | BIRC8 | Baculoviral IAP repeat-containing protein 8 | Homo sapiens (Human) | PR |
| Q13490 | BIRC2 | Baculoviral IAP repeat-containing protein 2 | Homo sapiens (Human) | EV |
| Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | Homo sapiens (Human) | SS |
| Q62210 | Birc2 | Baculoviral IAP repeat-containing protein 2 | Mus musculus (Mouse) | SS |
| O62640 | PIAP | Putative inhibitor of apoptosis | Sus scrofa (Pig) | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MAEQDVENDL | LDYDEEEEPQ | APQESTPAPP | KKDIKGSYVS | IHSSGFRDFL | LKPELLRAIV |
| 70 | 80 | 90 | 100 | 110 | 120 |
| DCGFEHPSEV | QHECIPQAIL | GMDVLCQAKS | GMGKTAVFVL | ATLQQIEPVN | GQVTVLVMCH |
| 130 | 140 | 150 | 160 | 170 | 180 |
| TRELAFQISK | EYERFSKYMP | SVKVSVFFGG | LSIKKDEEVL | KKNCPHVVVG | TPGRILALVR |
| 190 | 200 | 210 | 220 | 230 | 240 |
| NRSFSLKNVK | HFVLDECDKM | LEQLDMRRDV | QEIFRLTPHE | KQCMMFSATL | SKDIRPVCRK |
| 250 | 260 | 270 | 280 | 290 | 300 |
| FMQDPMEVFV | DDETKLTLHG | LQQYYVKLKD | SEKNRKLFDL | LDVLEFNQVI | IFVKSVQRCM |
| 310 | 320 | 330 | 340 | 350 | 360 |
| ALAQLLVEQN | FPAIAIHRGM | AQEERLSRYQ | QFKDFQRRIL | VATNLFGRGM | DIERVNIVFN |
| 370 | 380 | 390 | 400 | 410 | 420 |
| YDMPEDSDTY | LHRVARAGRF | GTKGLAITFV | SDENDAKILN | DVQDRFEVNV | AELPEEIDIS |
| TYIEQSR |